Hypergammaglobulinemia
Hypergammaglobulinemia
Explore linked clinical trials. Standard reference: MESH:M001082365 results ยท Page 1 of 3
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-10-07 | NCT07393282 | |
| A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma | Active, not recruiting | Phase 1 | 2026-10-07 | NCT02886065 | |
| Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, precancerous condition, smoldering plasma cell myeloma | Recruiting | Not stated | 2026-10-07 | NCT02726750 | |
| Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, precancerous condition, smoldering plasma cell myeloma | Recruiting | Not stated | 2026-10-06 | NCT05136807 | |
| Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma | Active, not recruiting | Phase 2 | 2026-10-06 | NCT02960555 | |
| A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Recruiting | Not applicable | 2026-10-05 | NCT06055894 | |
| Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, light chain deposition disease, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma | Active, not recruiting | Phase 3 | 2026-10-01 | NCT01169337 | |
| A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, precancerous condition, proteostasis deficiencies, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2026-09-25 | NCT06768489 | |
| A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, precancerous condition, smoldering plasma cell myeloma | Active, not recruiting | Not applicable | 2026-09-21 | NCT04920084 | |
| A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH | Abnormalities, Multiple, Blood Protein Disorders, Castleman disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, POEMS syndrome, Skin and Connective Tissue Diseases, amyloidosis, cardiovascular disorder, cryoglobulinemia, heavy chain deposition disease, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, light chain deposition disease, lymphatic system disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, nervous system disorder, neuromuscular disease, peripheral nervous system disorder, plasma cell leukemia, plasma cell neoplasm, polyneuropathy, precancerous condition, proteostasis deficiencies, skin disorder, skin vascular disease, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Recruiting | Not stated | 2026-09-16 | NCT05283993 | |
| Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma | Active, not recruiting | Phase 2 | 2026-09-02 | NCT06183489 | |
| Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-08-26 | NCT00114101 | |
| Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, precancerous condition, smoldering plasma cell myeloma | Not yet recruiting | Not applicable | 2026-08-24 | NCT06987708 | |
| Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma | Recruiting | Phase 3 | 2026-08-19 | NCT03937635 | |
| Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Active, not recruiting | Not applicable | 2026-08-18 | NCT05831358 | |
| MGUS/MM Awareness and Genetics Insights Campaign (MAGIC) Screening Study | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, monoclonal gammopathy of uncertain significance | Enrolling by invitation | Not stated | 2026-08-11 | NCT06472830 | |
| Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma | Active, not recruiting | Early phase 1 | 2026-07-17 | NCT02603887 | |
| Immuno-PRISM (PRecision Intervention Smoldering Myeloma) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-07-16 | NCT05469893 | |
| CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Recruiting | Not stated | 2026-07-13 | NCT06644625 | |
| A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, precancerous condition, smoldering plasma cell myeloma | Recruiting | Phase 2 | 2026-07-08 | NCT06140524 | |
| Early Screening for Multiple Myeloma Based on Liquid Biopsy cfDNA Fragmentomics | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Not yet recruiting | Not stated | 2026-07-06 | NCT07684274 | |
| Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, plasma cell myeloma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Not stated | 2026-06-10 | NCT06559033 | |
| Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine Imaging | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, plasma cell neoplasm, primary systemic amyloidosis, proteostasis deficiencies, vascular disorder, vascular hemostatic disease | Not yet recruiting | Not applicable | 2026-06-03 | NCT07624760 | |
| Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma | Recruiting | Phase 2 | 2026-06-01 | NCT04776395 | |
| Ilaris NIS in Korea | Blood Protein Disorders, Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Chronic Disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Hypersensitivity, Immediate, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Peroxisomal Disorders, Skin and Connective Tissue Diseases, TNF receptor 1-associated periodic fever syndrome, arthritic joint disease, arthropathy, autoimmune disease, brain disorder, central nervous system disorder, chronic inducible urticaria, chronic urticaria, cold urticaria, connective tissue disorder, cryopyrin-associated periodic syndrome, hematologic disorder, hereditary disease, hereditary periodic fever syndrome, hereditary skin disorder, immune system disorder, immunoproliferative disorder, inborn errors of metabolism, juvenile idiopathic arthritis, metabolic disease, mevalonate kinase deficiency, musculoskeletal system disorder, nervous system disorder, rheumatic disorder, skin disorder, skin vascular disease, urticaria | Recruiting | Not stated | 2026-05-19 | NCT06838143 |